Conclusions
1 evidence topic · 17 sources
Summary
Onvuzosiran (ADX-324) is an investigational small interfering RNA that targets prekallikrein, and its sponsor states that it has “no products approved for commercial sale”. The FDA granted orphan drug designation for the treatment of patients with HAE in October 2025 and Fast Track designation for prophylaxis to prevent HAE attacks in August 2026. The phase 3 STOP-HAE trial began in August 2025 and has an estimated primary completion date of 2027-11-30; the sponsor expects topline data by the end of 2027 and anticipates a New Drug Application in 2028 if the data are positive. No price has been published, and no cost-effectiveness or budget impact analysis of onvuzosiran was identified.
The clinical evidence comes from one phase 1/2 trial (NCT05691361). In healthy volunteers, a single dose of 300 mg plus or minus 25 mg (n=5) reduced prekallikrein-kallikrein by a mean of 93% at nadir and 80% at 6 months in the AAAAI poster and the February 2026 release; the prospectus reports more than 90% and at least 80% for the same dose group. The open-label phase 2a part has dosed 3 participants with HAE every 6 months (1 at 122.5 mg and 2 at 245 mg), doses lower or less frequent than the phase 3 regimens of 300 mg every 6 months and 240 mg every 3 months. All 3 participants were attack-free for 3 months after the first dose, and the November 2026 presentation reports that 1 participant (245 mg every 6 months) had one mild attack on Day 153 and then remained attack-free for 21 consecutive months as of the November 5, 2026 cutoff. Sponsor documents report that no attacks occurred while prekallikrein suppression exceeded 80%. No treatment-related serious adverse events were reported as of the August 5, 2026 safety cutoff; injection site reactions, headache, laboratory changes in blood creatine phosphokinase, and ALT/AST increases are listed as the most common adverse events, without counts.
This evidence has four limits. It rests on 3 participants with HAE in an uncontrolled study, with no published baseline or on-treatment attack rates, baseline characteristics, or quality-of-life results. It is reported only in congress abstracts and posters, a press release, a corporate presentation, and SEC filings; no peer-reviewed full article was identified, and the registry record shows “No Results Posted”. The documents disagree on the number of healthy volunteers (43 or 49), on the dose to which the 94% nadir reduction is attributed, and on the suppression threshold proposed for attack prevention (greater than 80% or greater than 70%). No head-to-head trial or indirect comparison that includes onvuzosiran was identified, and STOP-HAE compares it with placebo alone.
Questions a P&T committee would need answered when phase 3 results and a price are published:
- The reduction in time-normalized attack rate from Day 22 to Week 25 with 300 mg every 6 months compared with placebo (the primary endpoint), the corresponding result for 240 mg every 3 months, and the proportion of participants attack-free with each regimen.
- Protection during the first weeks of treatment: attacks before Day 22 are excluded from the primary endpoint, the sponsor reports a lag of about 22 days between the first dose and full inhibition, and STOP-HAE requires washout of previous long-term prophylaxis, so the trial does not test continuing an existing agent during that lag.
- Durability and safety beyond 6 months, including the hepatic enzyme and creatine phosphokinase changes, which the extension study (onvuzosiran for up to 3 years; estimated primary completion 2030-06-30) is designed to address.
- Applicability: STOP-HAE enrolls adults aged 18 years or older with type I or type II HAE and excludes clinically significant renal disease, so no data address children, HAE with normal C1 inhibitor, or renal impairment.
- Whether onvuzosiran would be self-administered or given by a health care professional, which the sources do not state.
- The annual cost relative to current agents, whose 2025 estimated annual wholesale acquisition costs range from $579,885 (berotralstat) to $747,006 (donidalorsen every 4 weeks), and the resulting budget impact.
Onvuzosiran appears in no guideline list of first-line prophylactic agents, which comprises subcutaneous plasma-derived C1 inhibitor, lanadelumab, berotralstat, garadacimab, and donidalorsen. The sponsor compares it with donidalorsen, which acts on the same target: in OASIS-HAE, donidalorsen 80 mg reduced trough prekallikrein by 73% every 4 weeks and 47% every 8 weeks, and the sponsor describes its attack-free rate as “only 35% (Q8W) to 53% (Q4W)”. The sponsor's target profile for onvuzosiran is a greater than 90% reduction in monthly attacks with greater than 75% of patients attack-free on Q3M or Q6M dosing, and the sponsor states that cross-study comparisons “should be interpreted with caution”. A network meta-analysis of approved agents, which does not include onvuzosiran, ranked garadacimab (SUCRA 94%) and lanadelumab every 2 weeks (SUCRA 83%) highest for attack-rate reduction. A second prekallikrein-directed siRNA, BW-20805, reported reductions in monthly attack rate of 83% to 96% across three regimens in a study of 25 participants with HAE.